CJC-1295 Ipamorelin pairs a long-acting GHRH analogue with a selective ghrelin-receptor agonist to amplify the body's own growth-hormone pulse.

The short version

CJC-1295 Ipamorelin is two research peptides used together. CJC-1295 is a long-acting copy of GHRH — the natural signal your brain sends to release growth hormone (GH). Ipamorelin is a "GHRP": it pushes the same GH-making cells through a second, separate switch (the ghrelin receptor). Because the two work through different doors, using them together produces a bigger GH burst than either one alone, and that extra GH raises a downstream messenger called IGF-1 ^[1][3][4]. People in research-use communities reach for this pair hoping for better sleep, faster recovery, and a slow shift toward a leaner build. Here is the honest catch: neither peptide is FDA-approved, and this exact fixed combination has never been studied in a real human trial — so the benefits are extrapolated, not proven for the blend itself. What people actually report — including the downsides — is laid out on the effects page.

Cjc-1295 ipamorelin: two complementary signals, one larger pulse

Co-stimulating the GHRH receptor and the ghrelin receptor at the same time releases more growth hormone than hitting either pathway alone. In normal men, submaximal doses of a GHRP combined with GHRH released GH synergistically, the two acting through independent mechanisms ^[3]. At the receptor level, co-activating the cloned GH-secretagogue and GHRH receptors produced roughly twice the cAMP signal of GHRH activation alone ^[4]. CJC-1295 is the GHRH arm; ipamorelin is the GHRP arm. The design goal of the pairing is a supra-additive (bigger-than-the-sum) GH pulse with a clean side-effect profile — which is exactly where ipamorelin's selectivity matters.

What each half brings, on its own merits

CJC-1295 (with DAC) is engineered for staying power. A single subcutaneous dose raised mean plasma GH 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9 to 11 days in healthy adults; after repeat dosing, IGF-1 stayed above baseline up to 28 days ^[1]. That multi-day reach comes from a Drug Affinity Complex (DAC) — a small chemical handle that covalently bonds the peptide to albumin, a carrier protein in blood, so it isn't cleared in minutes ^[5].

Ipamorelin is the precise one. It was the first selective GH secretagogue: unlike older GHRPs it did not raise the stress hormones ACTH or cortisol above GHRH-stimulated levels, even at doses more than 200 times the amount needed for GH release, while still matching GHRP-6's GH efficacy in swine ^[2]. That selectivity is why it's the GHRP most often paired with a GHRH analogue.

The bone-growth signal — a concrete anabolic endpoint

GH release isn't an abstraction; in animal models it moves real tissue. Ipamorelin dose-dependently increased the longitudinal bone-growth rate in adult female rats (from about 42 to about 52 micrometers per day) over 15 days, an effect attributable to GH release ^[8]. Under a catabolic challenge it protected bone too: ipamorelin counteracted glucocorticoid-induced bone loss in rats, with periosteal bone-formation rate rising four-fold versus glucocorticoid alone ^[9]. Over a longer 12-week course, ipamorelin raised bone mineral content measured by DXA ^[10]. These are rodent findings — read them as mechanism, not as human dosing. The full picture, including the cjc 1295 ipamorelin benefits people report and the cautions that go with raising GH, is built out across this digest.

What this site is — and what it isn't

This is an independent editorial digest of the peer-reviewed literature on the CJC-1295 Ipamorelin combination. It is not a clinic, not a pharmacy, and not a place to buy anything. Neither peptide is FDA-approved for any human use, both are sold only as research chemicals, and both are prohibited at all times in sport under WADA Section S2 (peptide hormones and GH secretagogues). You'll find the mechanism in plain language on CJC-1295 Ipamorelin research, the human-reported CJC-1295 Ipamorelin effects clearly labeled as anecdotal, the doses studied in animals and early human PK work on dosage, and every source listed on CJC-1295 Ipamorelin references. Where the data is precise, this digest is precise. Where it's missing — and for the fixed blend, much of it is — it says so plainly.